PREVADDUCT
Dead / Abandoned — Abandoned — no statement of use filed (as of 18 Dec 2023)
What this means for you
This application is over — abandoned 18 Dec 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88912457
- Mark type
- Stylized text
- Filed
- 12 May 2020
- Published for opposition
- 15 Sept 2020
- Abandoned
- 18 Dec 2023
- Attorney of record
- Katherine Sullivan
Goods and services
- Class 005 — Pharmaceuticals: Dietary and nutritional supplements; Digestives for pharmaceutical purposes; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention of inflammation; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment and prevention of oxidative damage; Pharmaceutical preparations for the treatment and prevention of chronic inflammation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of chronic inflammation; Pharmaceutical preparations for the treatment of oxidative damage; Pharmaceutical preparations for the treatment of isoketal activity diseases and conditions; Pharmaceutical preparations for the treatment of musculoskeletal, cardiovascular, cardiopulmonary, and immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating asthma; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for inflammation; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Anti-inflammatory preparations; Chemical preparations for pharmaceutical or medical purposes, namely, for oxidative damage, isoketal activity and chronic inflammation; Chemical preparations for pharmaceutical or medical purposes, namely, for diseases resulting from oxidative damage, isoketal activity or inflammation; Food supplements, namely, anti-oxidants; Medical preparations for the treatment of oxidative damage, isoketal activity and chronic inflammation; Medicinal preparations for inflammation; Pharmaceutical products and preparations to prevent swelling in the legs; Preparation for the relief of pain
Owner
- Adduct Pharmaceutical, Inc., Ames, IA, US
- Adduct Pharmaceutical, Inc., Ames, IA, US
Prosecution history
- 18 Dec 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 18 Dec 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 12 May 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 May 2023 — SOU EXTENSION 5 GRANTED
- 07 May 2023 — SOU EXTENSION 5 FILED
- 11 May 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 07 May 2023 — SOU TEAS EXTENSION RECEIVED
- 12 Nov 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Nov 2022 — SOU EXTENSION 4 GRANTED
- 10 Nov 2022 — SOU EXTENSION 4 FILED
- 10 Nov 2022 — SOU TEAS EXTENSION RECEIVED
- 10 May 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 May 2022 — SOU EXTENSION 3 GRANTED
- 08 May 2022 — SOU EXTENSION 3 FILED
- 08 May 2022 — SOU TEAS EXTENSION RECEIVED